<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20548
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: July 15, 1998
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
9393 Towne Centre Drive, Suite 200; San Diego, California 93121-3016
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE> 2
Item 5. OTHER EVENTS
The registrant incorporates by reference herein the press release dated July 15,
1998, attached hereto as Exhibit 99.
Item 7. Financial Statements and Exhibits
(c) Exhibits
(i) Exhibit 99 -- Press Release dated July 15, 1998
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LIDAK PHARMACEUTICALS
DATE: July 27, 1998 By: /s/ GERALD J. YAKATAN
-------------------------
Gerald J. Yakatan, Ph.D.
President & Chief Executive Officer
<PAGE> 1
Exhibit 99.1
LIDAK Pharmaceuticals
9393 Towne Centre Drive, Suite 200
San Diego, CA 92121-3016
CONTACT: Ann Shanahan-Walsh
Media Relations Director
619/558-0364 x 212
FOR IMMEDIATE RELEASE
LIDAK PHARMACEUTICALS APPOINTS GREGORY HANSON CHIEF FINANCIAL
OFFICER - ANNOUNCES RESIGNATION OF JEFFERY WEINRESS
SAN DIEGO, CA: July 15, 1998: LIDAK Pharmaceuticals (Nasdaq: LDAKA)
announced today the appointment of Gregory Hanson as the company's chief
financial officer. He replaces Jeffery Weinress who recently resigned his
position as vice president and chief financial officer.
"Jeff's experience, commitment and considerable contributions to the
company will be missed. We all wish him success in his future endeavors," said
CEO and president Gerald J. Yakatan, Ph.D."
Gregory Hanson, currently the CFO for Xxsys Technologies, Inc., a San
Diego-based publicly-traded company focused on the commercialization of
advanced composite technologies, will make the transition to his new position
over the next several weeks.
Prior to his position at Xxsys, he served as a management consultant to
the Titan Corporation, a San Diego-based publicly-traded telecommunications
company, where he was responsible for the business development plan for a new
wholly-owned subsidiary. Following its formation, he continued to work for the
subsidiary's president as acting CFO and was instrumental in moving the company
through an orderly transition to a sustainable organization.
LIDAK Resignation
Page 2
Gregory Hanson earned a BS in Mechanical Engineering from Kansas State
University and received an MBA in Finance from the University of Michigan,
graduating with honors and ranking first in his class.
"We are very pleased to welcome Greg as a member of our management team,"
said Yakatan. "Greg's hands-on experience in a variety of high tech
environments is a definite asset to the company. He brings the spirit and
energy identifiable with the small, growth-oriented company. Our team looks
forward to moving ahead with the strategic plan focused on in-licensing
products to augment the LIDAK pipeline."
LIDAK Pharmaceuticals is a San Diego-based development staged company
engaged in the research, development and commercialization of innovative
pharmaceutical products. The company's first drug, LIDAKOL Cream, a topical
cream for the treatment of recurrent oral facial herpes infections, is
currently awaiting FDA marketing approval.
###
The information contained in this press release, including any forward looking
statements contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-K and other publicly available information
regarding the Company, copies of which are available from the Company upon
request. Such publicly available information sets forth many risks and
uncertainties related to the Company's business and such statements, including
risks and uncertainties related to drug development, clinical trials and
litigation. Final decisions made by the FDA, other regulatory agencies and the
courts are unpredictable and outside of the influence and/or control of the
Company.
